Aug 2026· International Journal of Drug Discovery and Pharmacology· Vol 5· 0 citations· 103 references
Abstract
Coronary artery disease (CAD) is a typical age-related chronic condition, with its development and progression spanning a long course of life and exhibiting significant inter-individual heterogeneity. Traditional risk assessment models based on chronological age and single risk factors are often insufficient to capture the cumulative physiological decline and the dynamic progression of disease. In this review, biological age, as a comprehensive indicator reflecting an individual’s true aging status, has gradually emerged as an important tool for understanding differences in CAD risk and disease progression. In recent years, various methods for assessing biological age have been applied in CAD research, primarily including composite biological age derived from routine clinical indicators, telomere length, and epigenetic clocks. Evidence suggests that different biological age markers provide complementary information and are suited into distinct applications. Among them, composite clinical biological age, based on routine clinical measurements, can dynamically reflect multi-system functional changes and has demonstrated feasibility and stability in CAD risk stratification, disease progression monitoring, and evaluation of intervention effects, highlighting its potential clinical utility. Telomere length and epigenetic clocks, on the other hand, provide supplementary information at the cellular and molecular regulatory levels regarding cumulative physiological burden and aging mechanisms. Looking forward, integrating molecular-level aging markers with composite clinical biological age to establish a multi-tiered assessment framework may improve early identification and precision intervention for CAD and other chronic diseases.
Peripheral artery disease (PAD) is a prevalent atherosclerotic disorder affecting over 113 million individuals worldwide, with its global burden projected to rise substantially amid population aging and increasing metabolic comorbidities, including type 2 diabetes mellitus (T2DM). Conventional diagnostic assessment, in...
Bo Chen, Wan Chen, Xiao-Hua Yu et al.· Clinica chimica acta; intern...· 0 citations
Background Biological ages capture aging signatures associated with aging-related outcomes, but most models use systemic and unimodal indices. The added value of organ-specific and multimodal information for assessing organ-specific disease associations remains unclear. Methods We enrolled 1,830 participants (77.81% ma...
Yi-Ming Wang, Hao Zhu, Xiao-Tong Liu et al.· Frontiers in Cardiovascular...· 0 citations
TyG BA composites provide a parsimonious summary of combined metabolic-aging burden and improve risk discrimination beyond conventional clinical factors, but should not be interpreted as superior to models retaining TyG and biological age separately.
Subclinical cardiovascular disease (SCVD) encompasses a spectrum of vascular abnormalities that emerge well before the onset of overt cardiovascular events. Although a wide range of metabolic, inflammatory, and vascular markers have been associated with SCVD, current assessment strategies remain largely dependent on in...
Jing Ran, Zong-Tao Chen· Cardiology in Review· 0 citations
CASCADE (Chronological Atherosclerosis Staging: Connecting Aging, Disease, and Environment), a conceptual framework that applies disease staging to atherosclerosis, is proposed as a hypothesis-generating framework, not a validated scoring system, and invites prospective evaluation of whether individuals traverse identi...
J. E. Montoya-Pérez, Juan R. Serna-Garza, A. E. Gracia-Ramos· Frontiers in Cardiovascular...· 0 citations
It is demonstrated that routine chest CT captures both shared and organ-specific patterns of biological aging and establish CT-derived organ aging as a quantitative imaging biomarker for assessing multi-organ health and long-term disease risk.
Junya Sato, Morteza Salehjahromi, Anas Zafar et al.· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.